Why Oscar Health, Inc. (OSCR) stock moved
Oscar Health, Inc. (OSCR) shares rose 1.7% to $29.60 as of July 21, 2026, a modest gain from the prior close of $29.10. BestStocks flagged the session as a major change for OSCR. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for OSCR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
OSCR climbed 1.7% to $29.60
OSCR rose 1.7% in its latest session, moving from $29.10 to $29.60.
What it means for Oscar Health, Inc. investors
For Oscar Health, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.7% session move; Oscar Health, Inc. (OSCR) moved +3.47% from $30.54 to $31.60 on 2026-07-13. Weighing against that: Oscar Health, Inc. (OSCR) moved -5.72% from $30.61 to $28.86 on July 16, 2026; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $24.20, implying -18.2% downside from $29.60. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 16 days out, the next report is the most likely near-term test of the move.
OSCR price reaction
OSCR last traded at $29.60, up $0.50 (+1.72%) from the previous close of $29.10. The session traded on 0.4× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Oscar Health, Inc. (OSCR)
The consensus analyst price target on Oscar Health, Inc. (OSCR) is $24.20, 18.2% below the recent $29.60. Over the past 90 days analysts logged 1 upgrade, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on OSCR line up.
The bullish case
- The Street's most bullish target is $35.00 (+18.2%).
- 1 analyst upgrade in the past 90 days, most recently Barclays to Overweight (2026-06-10).
- Positive 1.7% session move.
- Oscar Health, Inc. (OSCR) moved +3.47% from $30.54 to $31.60 on 2026-07-13.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $24.20 sits 18.2% below the recent $29.60, so the average target sees limited room to run.
- The most bearish analyst target is $16.00 (-45.9%).
- Oscar Health, Inc. (OSCR) moved -5.72% from $30.61 to $28.86 on July 16, 2026.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for OSCR
Frequently asked questions about OSCR
Why did Oscar Health, Inc. (OSCR) stock move?
OSCR rose 1.7% to $29.60. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did OSCR stock rise?
OSCR gained 1.72% ($0.50) versus the prior close of $29.10, last trading at $29.60 on 0.4× average volume.
When is Oscar Health, Inc.'s next earnings date?
OSCR's next earnings report is estimated for 2026-08-06 — about 16 days away.
What is the analyst price target for OSCR?
The consensus analyst price target for OSCR is $24.20, about 18.2% below the current $29.60. Over the past 90 days, analysts recorded 1 upgrade, 4 maintains, and 0 downgrades.
How BestStocks tracks OSCR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared OSCR-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for OSCR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.